TELEFLEX INC
Company Information
Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 550 E SWEDESFORD RD, WAYNE, PA, 19087
Mailing Address 550 E SWEDESFORD RD, WAYNE, PA, 19087
Phone 610-225-6800
Fiscal Year End 1231
EIN 231147939
Financial Overview
FY2025
$356.33M
Net Income
$7.10B
Total Assets
$3.82B
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
Annual Reports
10-K February 27, 2026
- Teleflex reported strong FY2023 net revenues of $2.95 billion, an increase of 5.8% (constant currency), driven by core segments and strategic acquisitions.
- The company underwent significant strategic transformation, optimizing its portfolio through key acquisitions in high-growth markets and divestitures of non-core assets.
Material Events
8-K Strategy Change March 27, 2026
High Impact
- Strategic divestiture of three business units to focus on high-growth vascular and interventional access sectors.
- Planned $1.8 billion capital infusion from asset sales to deleverage the balance sheet.
8-K Strategy Change December 9, 2025
High Impact
- Teleflex is divesting its Original Equipment Manufacturing (OEM) and Development Services business and its Acute Care and Interventional Urology segments.
- The divestitures will generate a total of $2.03 billion in cash for Teleflex ($1.5 billion from OEM sale, $530 million from Acute Care/Interventional Urology sale).
Related Companies
Companies in the same industry (SIC: 3841)
OSR Holdings, Inc.
OSRH Surgical & Medical Instruments & Apparatus
NEXGEL, INC.
NXGL Surgical & Medical Instruments & Apparatus
Catheter Precision, Inc.
VTAK Surgical & Medical Instruments & Apparatus
VYCOR MEDICAL INC
VYCO Surgical & Medical Instruments & Apparatus
Co-Diagnostics, Inc.
CODX Surgical & Medical Instruments & Apparatus
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.